secwatch.observer — SEC 8-K summary
======================================

Issuer:     KYNTRA BIO, INC. (KYNB)
CIK:        0000921299
Form:       8-K
Filed at:   2024-08-07T23:59:59+00:00
Accession:  0000950170-24-092967
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 2.05
LLM model:  deepseek-v4-flash:cloud@v2

FibroGen cuts 75% of U.S. workforce (127 employees); charges $16-18M
--------------------------------------------------------------------

- Workforce reduction of ~75% (127 U.S. employees) effective Aug 2, 2024.
- Estimated non-recurring charges of $16-18M for severance, payroll, benefits.
- Majority of charges expected in H2 2024; cash payments substantially complete by Q1 2025.
- Restructuring follows negative pamrevlumab clinical trial data announced earlier that week.
- Potential position eliminations subject to legal requirements; process may extend beyond Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921299/000095017024092967/0000950170-24-092967-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921299/000095017024092967/fgen-20240802.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-092967

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer